Your browser is no longer supported. Please, upgrade your browser.
XON Intrexon Corporation weekly Stock Chart
XON [NYSE]
Intrexon Corporation
Index- P/E- EPS (ttm)-0.32 Insider Own0.40% Shs Outstand129.98M Perf Week-4.32%
Market Cap2.10B Forward P/E- EPS next Y-0.77 Insider Trans192.34% Shs Float128.49M Perf Month0.25%
Income-40.20M PEG- EPS next Q-0.25 Inst Own85.40% Short Float18.18% Perf Quarter-5.56%
Sales221.30M P/S9.49 EPS this Y84.40% Inst Trans10.45% Short Ratio19.83 Perf Half Y22.44%
Book/sh4.33 P/B3.73 EPS next Y29.40% ROA-14.30% Target Price30.80 Perf Year-29.23%
Cash/sh0.95 P/C17.00 EPS next 5Y34.90% ROE-23.50% 52W Range10.26 - 25.88 Perf YTD40.19%
Dividend- P/FCF- EPS past 5Y58.00% ROI-8.80% 52W High-36.40% Beta1.05
Dividend %- Quick Ratio1.90 Sales past 5Y75.80% Gross Margin71.70% 52W Low60.51% ATR0.63
Employees906 Current Ratio2.20 Sales Q/Q-18.40% Oper. Margin-70.10% RSI (14)46.63 Volatility3.47% 3.17%
OptionableYes Debt/Eq0.01 EPS Q/Q-24.60% Profit Margin-57.70% Rel Volume0.92 Prev Close16.15
ShortableYes LT Debt/Eq0.01 EarningsMay 10 AMC Payout- Avg Volume1.18M Price16.46
Recom2.20 SMA200.74% SMA50-4.83% SMA2003.98% Volume1,085,391 Change1.92%
Nov-10-17Reiterated Stifel Buy $57 → $39
Nov-10-17Reiterated Stifel Buy $39 → $57
Dec-29-16Initiated Northland Capital Outperform $40
May-03-16Initiated JMP Securities Mkt Outperform
Mar-01-16Reiterated Stifel Buy $69 → $57
Mar-01-16Reiterated Mizuho Neutral $28 → $29
Jan-25-16Reiterated Mizuho Neutral $42 → $28
Nov-11-15Upgrade Mizuho Underperform → Neutral $45 → $42
Oct-19-15Reiterated Wunderlich Buy $70 → $50
Oct-14-15Initiated BofA/Merrill Neutral $35
Sep-21-15Initiated Stifel Buy $69
Aug-11-15Downgrade Mizuho Neutral → Underperform $45
Aug-11-15Downgrade JP Morgan Overweight → Neutral
Jul-27-15Reiterated Wunderlich Buy $55 → $70
Jun-09-15Initiated Wunderlich Buy $55
Mar-10-15Downgrade Mizuho Buy → Neutral $14
Mar-03-15Reiterated Mizuho Buy $32 → $50
Jan-23-15Reiterated Mizuho Buy $30 → $32
Sep-03-13Initiated Mizuho Buy $30
Sep-03-13Initiated Barclays Equal Weight $25
Jun-18-18 07:30AM  Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy GlobeNewswire
Jun-11-18 04:12AM  Intrexon (XON) Down 9.2% Since Earnings Report: Can It Rebound? Zacks
Jun-04-18 07:56AM  Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-31-18 10:26AM  Does Intrexon Corporations (NYSE:XON) Latest Financial Perfomance Look Strong? Simply Wall St.
May-29-18 08:00AM  Isolation and Recombinant Expression of Key Enzyme for Opioid Production PR Newswire
May-24-18 07:00AM  Oxitec Launches Field Trial in Brazil for Next Generation Addition to Friendly Mosquitoes Platform PR Newswire
May-23-18 08:11AM  The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti PR Newswire
May-21-18 08:00AM  Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001 PR Newswire
May-16-18 05:00PM  Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
07:45AM  Recent Analysis Shows H&R Block, Opko Health, Geron, Cardinal Health, Corning, and Intrexon Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
May-14-18 08:00AM  Todays Research Reports on Stocks to Watch: Intrexon and Supernus Pharmaceuticals ACCESSWIRE
08:00AM  Intrexon to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference PR Newswire
07:10AM  Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks ACCESSWIRE
May-12-18 01:47AM  Edited Transcript of XON earnings conference call or presentation 10-May-18 9:30pm GMT Thomson Reuters StreetEvents
May-11-18 04:00PM  Here's What's Causing Intrexon to Tumble 20% Today Motley Fool -19.64%
09:42AM  Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss Zacks
08:30AM  Today's Research Reports on Trending Tickers: Intrexon Corporation and Synergy Pharmaceuticals ACCESSWIRE
May-10-18 04:05PM  Intrexon Announces First Quarter 2018 Financial Results PR Newswire
04:01PM  Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-08-18 04:45PM  AquaBounty Technologies, Inc. Results for the quarter ended March 31, 2018 GlobeNewswire
May-03-18 08:00AM  Intrexon to Announce First Quarter 2018 Financial Results on May 10th PR Newswire
May-02-18 10:54AM  What's in Store for Intrexon (XON) This Earnings Season? Zacks
07:57AM  Ziopharm Oncology to Announce First Quarter 2018 Financial Results, Host Conference Call May 10 GlobeNewswire
Apr-27-18 11:15AM  AquaBounty Technologies, Inc. Announces FDA Approval of First U.S. Facility for Commercial Production of AquAdvantage Salmon GlobeNewswire
Apr-16-18 07:00AM  Exemplar Genetics Rare Neurological Disease Model Cleared by FDA for Commercial Research Use PR Newswire
Apr-13-18 11:43AM  Is Intrexon Corporation (NYSE:XON) As Strong As Its Balance Sheet Indicates? Simply Wall St.
Apr-06-18 08:19AM  Better Buy: Intrexon Corporation vs. Inovio Pharmaceuticals Inc. Motley Fool
Apr-03-18 08:20AM  Todays Research Reports on Trending Tickers: Intrexon and Portola Pharmaceuticals ACCESSWIRE +7.09%
Apr-02-18 04:11AM  Why Is Intrexon (XON) Up 18.8% Since Its Last Earnings Report? Zacks
Mar-29-18 09:25AM  ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes PR Newswire
Mar-13-18 09:00AM  Newman Ferrara LLP Announces Corporate Governance Investigation of Intrexon Corporation - XON Business Wire
Mar-12-18 09:10AM  Todays Research Reports on Trending Tickers: Intrexon and Opko Health ACCESSWIRE
09:00AM  Todays Research Reports on Trending Tickers: QEP Resources and Exxon Mobil ACCESSWIRE
Mar-08-18 04:30PM  AquaBounty Technologies, Inc. Results for the year ended December 31, 2017 GlobeNewswire
07:40AM  Detailed Research: Economic Perspectives on Cardtronics, Helix Energy, Plains Group Holdings, Vista Outdoor, Intrexon, and Zimmer Biomet What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-05-18 01:00PM  Dollar Tree Is One of 11 Stocks That Are Poised to Change Direction TheStreet.com
Mar-03-18 04:11PM  Edited Transcript of XON earnings conference call or presentation 1-Mar-18 10:30pm GMT Thomson Reuters StreetEvents
Mar-02-18 12:32PM  Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat Zacks +24.73%
Mar-01-18 04:05PM  Intrexon Announces Fourth Quarter and Full Year 2017 Financial Results PR Newswire
04:01PM  Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
01:30PM  Intrexon Corporation to Host Earnings Call ACCESSWIRE
11:13AM  A Preview Of Intrexon's Q4 Earnings Benzinga
Feb-26-18 09:04PM  What's in Store for Intrexon (XON) This Earnings Season? Zacks
Feb-22-18 08:00AM  Intrexon to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1st PR Newswire
Feb-13-18 07:15AM  Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1 GlobeNewswire
Feb-12-18 07:00AM  Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond GlobeNewswire
Feb-06-18 10:22AM  See the D.C.-area stocks hit hardest in the last week American City Business Journals +8.41%
08:55AM  Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance GlobeNewswire
Feb-01-18 08:20AM  Todays Research Reports on Trending Tickers: Incyte Corporation and Intrexon Corporation ACCESSWIRE
Jan-30-18 08:00AM  Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) GlobeNewswire -5.68%
Jan-29-18 05:39PM  First Eagle Fund of America 4th Quarter Commentary GuruFocus.com
09:57AM  Weekly CEO Buys Highlight GuruFocus.com
Jan-28-18 03:18PM  Better Buy: Intrexon Corporation vs. Celgene Motley Fool
Jan-19-18 04:34PM  Why IBM, GNC Holdings, and Intrexon Slumped Today Motley Fool
10:41AM  Intrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters PR Newswire
Jan-17-18 09:16AM  Intrexon Prices Public Offering of Common Stock PR Newswire
Jan-16-18 04:15PM  Intrexon Announces Proposed Public Offering of Common Stock PR Newswire -6.39%
Jan-12-18 09:20AM  AquaBounty Technologies, Inc. Announces $12 Million Underwritten Public Offering GlobeNewswire +11.27%
08:05AM  See what the IHS Markit Score report has to say about Intrexon Corp. Markit
Jan-10-18 08:05AM  See what the IHS Markit Score report has to say about Intrexon Corp. Markit
Jan-09-18 07:00AM  Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire +7.55%
Jan-04-18 08:35AM  Intrexon's ActoBio Therapeutics to Present at Biotech Showcase 2018 on January 8 PR Newswire -8.45%
08:30AM  Intrexon to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-03-18 03:52PM  A Cash Infusion From the Boss Props Up Intrexon -- For Now Barrons.com
Jan-02-18 08:00AM  Intrexon Corporation Annual CEO Letter PR Newswire +16.93%
Dec-27-17 12:06PM  ETFs with exposure to Intrexon Corp. : December 27, 2017 Capital Cube
Dec-26-17 08:55AM  Intrexon Corp. :XON-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017 Capital Cube
Dec-21-17 04:05PM  ZIOPHARM to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-14-17 02:18PM  ETFs with exposure to Intrexon Corp. : December 14, 2017 Capital Cube -6.44%
Dec-06-17 08:43AM  Why Intrexon (XON) Could Be Positioned for a Slump Zacks
Nov-28-17 08:06AM  Intrexon Corporation (XON)s Earnings Grew 24.8%, Is It Enough? Simply Wall St.
08:04AM  See what the IHS Markit Score report has to say about Intrexon Corp. Markit
Nov-27-17 08:20AM  Report: Developing Opportunities within Social Reality, The Finish Line, Facebook, Organovo, Plug Power, and Intrexon Future Expectations, Projections Moving into 2018 GlobeNewswire
08:00AM  Intrexon Announces Key Management Appointments PR Newswire
Nov-26-17 07:21AM  Edited Transcript of XON earnings conference call or presentation 9-Nov-17 10:30pm GMT Thomson Reuters StreetEvents
Nov-22-17 08:03AM  See what the IHS Markit Score report has to say about Intrexon Corp. Markit +7.84%
Nov-20-17 07:00AM  ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting GlobeNewswire
Nov-17-17 08:00AM  Todays Research Reports on Trending Tickers: Egalet Corporation and Intrexon Corporation ACCESSWIRE -5.65%
07:00AM  ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 a.m. ET to Discuss Updated Clinical Data Presented at the 2017 Annual Meeting of the Society for Neuro-Oncology GlobeNewswire
Nov-16-17 07:00AM  AquaBounty wins Gold Leaf Award for Best Emerging Agriculture Company from BIOTECanada GlobeNewswire +7.67%
05:54AM  Bill Miller, Kris Jenner share stocks they've got their eye on American City Business Journals
Nov-15-17 08:20AM  Todays Research Reports on Trending Tickers: Array BioPharma and Intrexon Corporation ACCESSWIRE
08:05AM  Here's What You Need to Know About Intrexon's Third-Quarter 2017 Earnings Motley Fool
07:30AM  Featured Company News - Zymeworks Enters Into License Agreement with Janssen Biotech to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics ACCESSWIRE
Nov-14-17 08:55AM  Intrexon (XON) in Focus: Stock Moves 6.5% Higher Zacks
Nov-12-17 07:00PM  Is Peak Permian Only 3 Years Away? Oilprice.com
Nov-10-17 05:40PM  Why Intrexon Corporation Stock Got Crushed Today Motley Fool -25.63%
04:05PM  ZIOPHARM to Present at the Stifel 2017 Healthcare Conference GlobeNewswire
08:49AM  Intrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss Zacks
08:00AM  Intrexon to Present at the Stifel 2017 Healthcare Conference PR Newswire
Nov-09-17 04:05PM  Intrexon Announces Third Quarter 2017 Financial Results PR Newswire
03:00PM  Intrexon Corporation to Host Earnings Call ACCESSWIRE
08:35AM  Why Intrexon Corporation (XON) Could Be A Buy Simply Wall St.
Nov-08-17 08:16AM  Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND Zacks
Nov-06-17 04:05PM  ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities GlobeNewswire
07:00AM  ZIOPHARM Announces Four Presentation Abstracts at the 2017 Annual Meeting of the Society for Neuro-Oncology GlobeNewswire
Nov-02-17 04:30PM  AquaBounty Technologies, Inc. Results for the quarter ended September 30, 2017 GlobeNewswire
Nov-01-17 09:37AM  ZIOPHARM Announces Five Abstracts Accepted for Presentation at the 2017 American Society of Hematology Annual Meeting GlobeNewswire
08:00AM  Intrexon to Announce Third Quarter 2017 Financial Results on November 9th PR Newswire
Oct-31-17 05:58PM  What's in Store for Intrexon (XON) This Earnings Season? Zacks
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALVAREZ CESAR LDirectorFeb 20Option Exercise2.648,90623,512114,849Feb 22 04:51 PM
Frank StevenDirectorFeb 12Option Exercise2.648,90623,512189,093Feb 14 08:06 PM
KIRK RANDAL JChief Executive OfficerJan 19Buy12.501,000,00012,500,0007,782,622Jan 22 09:04 AM
KIRK RANDAL J10% OwnerDec 11Buy0.772,727,2732,100,0005,773,626Dec 13 05:28 PM
Last Andrew J.Chief Operating OfficerNov 13Buy12.102,00024,2004,000Nov 15 04:17 PM
Reed Thomas D.Chief Science OfficerOct 16Option Exercise2.6438,598101,899102,715Oct 17 04:59 PM
SHAPIRO ROBERT BDirectorAug 22Buy17.502,85049,88382,966Aug 23 04:34 PM
Gupta Vinita DDirectorAug 22Buy17.613,00052,8303,000Aug 23 04:37 PM
Last Andrew J.Chief Operating OfficerAug 14Buy19.992,00039,9802,000Aug 15 01:14 PM
Lehr Donald P.Chief Legal OfficerAug 11Buy18.331,09420,05328,249Aug 11 01:08 PM
Perez Jeffrey ThomasSVP, IP AffairsAug 11Buy17.891,00017,89012,537Aug 11 01:04 PM
KINDLER JEFFREY BDirectorAug 11Buy18.325,44099,66171,762Aug 15 01:15 PM
MITCHELL DEAN JDirectorAug 11Buy18.335,00091,64018,103Aug 11 01:03 PM
KIRK RANDAL JChief Executive OfficerAug 11Buy18.85132,6252,499,9816,782,622Aug 14 08:57 AM
Nimrodi NirSVP-Corporate DevelopmentAug 11Buy18.753,36963,1697,369Aug 14 08:33 AM
Sterling Rick L.Chief Financial OfficerJul 07Option Exercise2.6468,252180,18574,621Jul 10 08:32 AM